B
GEVA

Baird’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Baird’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-7,053
Closed -$654K – 1379
2014
Q4 		$654K Buy
7,053
+59
+0.8% +$4.66K 0.01% 862
2014
Q3 		$481K Buy
6,994
+1,135
+19% +$81.3K 0.01% 842
2014
Q2 		$614K Buy
+5,859
New +$498K 0.01% 787

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Baird's GEVA Position: Q1 2015 in Review

Baird sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 7,053 shares — an estimated $654K sold.

Baird first reported a position in GEVA in Q2 2014 and held it in 3 quarters. The position peaked at $654K in Q4 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

  • Baird reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Baird sold 7,053 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $654K.
  • Baird first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2014 and held it in 3 quarters.
  • Baird's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $654K in Q4 2014.
  • 130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.